分子靶向抗肿瘤药物的不良反应及其处理对策  

Prevention and Treatments for Adverse Drug Reactions of Targeted Anticancer Drugs

作　　者：贾守薇[1] 刘韬[1] 黄红兵[1] 

机构地区：[1]中山大学肿瘤防治中心,华南肿瘤学国家重点实验室,肿瘤医学协同创新中心,广东广州510060

出　　处：《肿瘤药学》2014年第1期2-9,共8页Anti-Tumor Pharmacy

摘　　要：目前已有多种分子靶向抗肿瘤药物在我国上市,靶向治疗药物以其显著的疗效和良好的耐受性在临床上得到了广泛的应用,很多恶性肿瘤患者已从中获益。早期快速诊断并采取有效干预措施是改善肿瘤患者预后的重要手段,对改善患者生活质量和提高靶向治疗效果也尤为重要。本文对近年来分子靶向抗肿瘤药物的相关文献进行分析归纳,从皮肤系统、消化系统、循环系统、血液系统等多方面对分子靶向药物的不良反应及其处理对策进行了综述,旨在为国内临床医药人员的实际工作提供参考借鉴,以期制定良好的治疗方案并减少药物的不良反应。Currently, a number of molecular targeting drugs have been already approved by State Food and Drug Adminis- tration of China. Great advances have been achieved in the field of tumor targeted therapies in the last few years. The emergence of new targeted anticaneer therapies promises more efficient. Clinical benefits are striking for patients with malignancy. Gener- ally, they are well tolerated, and toxicities are commonly mild to moderate and can be handled rapidly. However, there are still some serious, even life-threaten adverse events. Early and rapid diagnosis, timely effective treatments are the keys to improve patient prognosis, and also important to improve the therapeutic efficacy and the quality of life for patients. This review sum-marized and analyzed the prevention and treatments of adverse drug reactions for this kind of agents, including those in dermal, digestive, circulatory and hematological systems, so as to provide references for domestic clinical medical personnel and reduce the incidence of adverse drug reaction.

关 键 词：分子靶向药物 抗肿瘤 不良反应 对策 

分 类 号：R730.6[医药卫生—肿瘤]